FivepHusion collaborates with Treehill, Syneos for Deflexifol
29 May 2023
License out/inDrug Approval
Preview
Source: Pharmaceutical Technology
5-FU and its biomodulator leucovorin are used for the treatment of various solid tumours. Credit: National Cancer InstituteCancer Institute on Unsplash.
FivepHusion has collaborated with Treehill Partners and Syneos Health to strategically progress development and commercialisation of its chemotherapeutic formulation Deflexifol in markets across the globe.
Under the partnership, Treehill will support FivepHusion with operational, strategic and transactional expertise along with integrated business development.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Bomedemstat Tosylate in Polycythemia Vera GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Anti-ILT4 GlobalData
View allCompanies IntelligenceFivePhusion Pty LtdTreehill Advisors LLPView all
Syneos will support the commercialisation and clinical development capabilities of FivepHusion.
FivepHusion CEO and managing director Dr Christian Toouli said: “By collaborating with Treehill Partners and Syneos Health, we believe we are positioned to successfully bring our development work on Deflexifol to global markets, including in the US, Europe and Asia.
“Through the combined strength and competency of three industry leaders, we intend to maximise our progress on the development of Deflexifol and quickly bring innovative oncology medicines to patients in need.”
Deflexifol is a new and optimised physiological pH formulation developed for the co-administration of the chemotherapeutic agent 5-fluorouracil (5-FU) and its biomodulator leucovorin (LV).
These drugs are used for the treatment of various solid tumours including gastric, pancreatic, colorectal and breast cancers.
Treehill partner and co-founder Ali Pashazadeh said: “By merging the scientific prowess of our clients with the clinical and commercial expertise of Syneos Health and Treehill’s healthcare advisory and execution capabilities, we are providing a unique ecosystem designed to help companies to flourish despite the current challenging market environment.”
Deflexifol is also being developed to treat paediatric ependymoma, a rare and deadly brain cancer affecting very young children.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.